Almirall, S.a.

This study tests the drug lebrikizumab in 520 adults and teens (ages 12+) with moderate-to-severe eczema. The goal is to see if a new, less frequent dosing schedule (every 12 weeks) works as well as the current one (every 4 weeks) at controlling skin symptoms. Participants will r…